Anita Rajasekhar

Anita Rajasekhar, M.D.

Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: rajasa@medicine.ufl.edu

About Anita Rajasekhar

Dr. Rajasekhar is a clinician and clinical investigator with a focus on benign hematology, specifically thrombosis and hemostasis. She is a member of the American Society of Hematology and the Hemostasis and Thrombosis Research Society.

Teaching Profile

Courses Taught
2019-2022
PAS5010 Intro to Medicine 1
2020-2024
BMS6631 Hematology
2018,2024
MDC6001 Intro Clin Practice
2022-2023
BMS6092 Research and Discovery
2023-2024
BMS6813 Introduction to Clinical Medicine 2A
2024
BMS6633 The Cv System
2024
BMS6852 Health Systems Science 2A
2024
BMS6850 Health Systems Science 1A

Board Certifications

  • Internal Medicine
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Cancer
  • Hematology
  • Hematology and Oncology
Areas of Interest
  • Cancer treatment information
  • Deep vein thrombosis

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-5278-9280

Publications

2024
Rapid recognition and optimal management of hemophilia in the emergency department: A quality improvement project.
Journal of the American College of Emergency Physicians open. 5(3) [DOI] 10.1002/emp2.13168. [PMID] 38699223.
2023
Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support.
Blood advances. 7(13):3058-3068 [DOI] 10.1182/bloodadvances.2021006140. [PMID] 35476017.
2023
Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.
Journal of the American Geriatrics Society. 71(12):3951-3953 [DOI] 10.1111/jgs.18579. [PMID] 37702478.
2023
Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13.
Haemophilia : the official journal of the World Federation of Hemophilia. 29(6):1638-1645 [DOI] 10.1111/hae.14891. [PMID] 37855744.
2023
Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.
Haemophilia : the official journal of the World Federation of Hemophilia. 29(5):1259-1268 [DOI] 10.1111/hae.14832. [PMID] 37584309.
2023
Reducing unnecessary premedication prior to parenteral iron therapy: A quality improvement project.
Transfusion. 63(9):1685-1691 [DOI] 10.1111/trf.17502. [PMID] 37587736.
2022
Efficacy and safety of pre-operative insertion of inferior vena cava filter in patients undergoing bariatric surgery: a systematic review.
Journal of thrombosis and thrombolysis. 54(3):502-523 [DOI] 10.1007/s11239-022-02689-3. [PMID] 35960423.
2022
Multidisciplinary Management of a Hemophilia A Patient Requiring Coronary Artery Bypass Graft Surgery.
Journal of cardiothoracic and vascular anesthesia. 36(2):534-538 [DOI] 10.1053/j.jvca.2021.10.029. [PMID] 34895963.
2022
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum.
Journal of thrombosis and thrombolysis. 54(2):197-210 [DOI] 10.1007/s11239-022-02643-3. [PMID] 35579732.
2022
Time is Blood: The Impact of Diagnostic Delays on Acquired Hemophilia A.
Cureus. 14(2) [DOI] 10.7759/cureus.22048. [PMID] 35340501.
2022
Use of cell salvage and HBOC-201 in a pregnant Jehovah’s Witness with sickle beta+thalassaemia undergoing emergency caesarean section.
BMJ case reports. 15(11) [DOI] 10.1136/bcr-2022-251368. [PMID] 36396327.
2021
A modeling approach to derive baseline risk estimates for GRADE recommendations: Concepts, development, and results of its application to the American Society of Hematology 2019 guidelines on prevention of venous thromboembolism in surgical hospitalized patients.
Journal of clinical epidemiology. 140:69-78 [DOI] 10.1016/j.jclinepi.2021.07.010. [PMID] 34284102.
2021
Administering RiaSTAP for Congenital Afibrinogenemia During Liver Transplant.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 19(3):269-272 [DOI] 10.6002/ect.2017.0316. [PMID] 29766777.
2021
AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.
Gastroenterology. 161(5):1615-1627.e1 [DOI] 10.1053/j.gastro.2021.08.015. [PMID] 34579936.
2021
In Response.
Anesthesia and analgesia. 133(5):e60-e61 [DOI] 10.1213/ANE.0000000000005726. [PMID] 34673734.
2021
The Society for Obstetric Anesthesia and Perinatology Interdisciplinary Consensus Statement on Neuraxial Procedures in Obstetric Patients With Thrombocytopenia.
Anesthesia and analgesia. 132(6):1531-1544 [DOI] 10.1213/ANE.0000000000005355. [PMID] 33861047.
2020
Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease.
Cureus. 12(12) [DOI] 10.7759/cureus.12161. [PMID] 33489573.
2020
Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?
Hematology. American Society of Hematology. Education Program. 2020(1):629-633 [DOI] 10.1182/hematology.2020000169. [PMID] 33275719.
2020
Inferior vena cava filters: a framework for evidence-based use.
Hematology. American Society of Hematology. Education Program. 2020(1):619-628 [DOI] 10.1182/hematology.2020000149. [PMID] 33275716.
2020
Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences.
Blood advances. 4(10):2351-2365 [DOI] 10.1182/bloodadvances.2020001768. [PMID] 32453843.
2020
Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism
Blood Advances. 4(12):2798-2809 [DOI] 10.1182/bloodadvances.2020002195. [PMID] 32574367.
2020
Society of Interventional Radiology Clinical Practice Guideline for Inferior Vena Cava Filters in the Treatment of Patients with Venous Thromboembolic Disease: Developed in collaboration with the American College of Cardiology, American College of Chest Physicians, American College of Surgeons Committee on Trauma, American Heart Association, Society for Vascular Surgery, and Society for Vascular Medicine.
Journal of vascular and interventional radiology : JVIR. 31(10):1529-1544 [DOI] 10.1016/j.jvir.2020.06.014. [PMID] 32919823.
2020
Systems-based hematology: highlighting successes and next steps.
Blood advances. 4(18):4574-4583 [DOI] 10.1182/bloodadvances.2020002947. [PMID] 32960959.
2019
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.
Blood advances. 3(23):3898-3944 [DOI] 10.1182/bloodadvances.2019000975. [PMID] 31794602.
2019
Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans.
Blood advances. 3(21):3278-3286 [DOI] 10.1182/bloodadvances.2019000569. [PMID] 31698456.
2019
Etiology and Management of Upper-Extremity Catheter-Related Thrombosis in Cancer Patients.
Cancer treatment and research. 179:117-137 [DOI] 10.1007/978-3-030-20315-3_8. [PMID] 31317484.
2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.
Blood advances. 2(22):3317-3359 [DOI] 10.1182/bloodadvances.2018024802. [PMID] 30482767.
2017
How I treat central venous access device-related upper extremity deep vein thrombosis.
Blood. 129(20):2727-2736 [DOI] 10.1182/blood-2016-08-693671. [PMID] 28373261.
2017
Thromboprophylaxis after Knee Arthroscopy.
The New England journal of medicine. 376(6):580-583 [DOI] 10.1056/NEJMclde1615661. [PMID] 28177874.
2016
Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology.
American journal of hematology. 91(8):787-92 [DOI] 10.1002/ajh.24412. [PMID] 27152483.
2015
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review.
Therapeutics and clinical risk management. 11:1273-82 [DOI] 10.2147/TCRM.S68010. [PMID] 26345156.
2015
Erratum to: Inferior vena cava filters: current best practices.
Journal of thrombosis and thrombolysis. 40(2) [DOI] 10.1007/s11239-015-1240-4. [PMID] 26063396.
2015
Inferior vena cava filters: current best practices.
Journal of thrombosis and thrombolysis. 39(3):315-27 [DOI] 10.1007/s11239-015-1187-5. [PMID] 25680894.
2014
Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
The American journal of the medical sciences. 347(3):254-5 [DOI] 10.1097/MAJ.0000000000000228. [PMID] 24553361.
2014
Five hematologic tests and treatments to question.
Hematology. American Society of Hematology. Education Program. 2014(1):599-603 [DOI] 10.1182/asheducation-2014.1.599. [PMID] 25696917.
2014
Five hematologic tests and treatments to question.
Blood. 124(24):3524-8 [DOI] 10.1182/blood-2014-09-599399. [PMID] 25472968.
2014
Inferior vena cava filters in trauma patients: a national practice patterns survey of U.S. Trauma centers.
The American surgeon. 80(12):1237-44 [PMID] 25513923.
2013
Vena cava filters for management of venous thromboembolism: a clinical review.
Blood reviews. 27(5):225-41 [DOI] 10.1016/j.blre.2013.07.001. [PMID] 23932118.
2012
A case series of atypical presentations of thrombotic thrombocytopenic purpura.
Journal of clinical apheresis. 27(4):221-6 [DOI] 10.1002/jca.21216. [PMID] 22467376.
2012
Effectiveness of Standardized Venous Thromboembolism Prophylaxis Order Sets in Patients Undergoing Abdominal Or Pelvic Surgery for Cancer
Blood. 120
2012
Inferior Vena Cava Filters in Trauma Patients: a National Practice Pattern Survey of Us Trauma Centers
Blood. 120
2012
Newer anticoagulants in critically ill patients.
Critical care clinics. 28(3):427-51, vii [DOI] 10.1016/j.ccc.2012.04.005. [PMID] 22713616.
2011
A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients.
The Journal of trauma. 71(2):323-8; discussion 328 [DOI] 10.1097/TA.0b013e318226ece1. [PMID] 21825934.
2011
Predicting Venous Thromboembolism in Trauma Patients Using East Criteria
. 17
2011
Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.
Journal of thrombosis and thrombolysis. 32(1):40-6 [DOI] 10.1007/s11239-010-0544-7. [PMID] 21221716.
2011
Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio.
Critical care medicine. 39(6):1507-13 [DOI] 10.1097/CCM.0b013e31820eb517. [PMID] 21336132.
2010
Inferior vena caval filter insertion prior to bariatric surgery: a systematic review of the literature.
Journal of thrombosis and haemostasis : JTH. 8(6):1266-70 [DOI] 10.1111/j.1538-7836.2010.03858.x. [PMID] 20345723.
2010
Meningitis due to group C Streptococcus: a case report and review of the literature.
Scandinavian journal of infectious diseases. 42(8):571-8 [DOI] 10.3109/00365541003754428. [PMID] 20632899.
2009
ASH evidence-based guidelines: what is the role of inferior vena cava filters in the perioperative prevention of venous thromboembolism in bariatric surgery patients?
Hematology. American Society of Hematology. Education Program. 302-4 [DOI] 10.1182/asheducation-2009.1.302. [PMID] 20008214.
2007
Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.
The oncologist. 12(11):1332-5 [PMID] 18055853.
1991
Diagnostic utility of fine-needle sampling without aspiration: a prospective study.
Diagnostic cytopathology. 7(5):473-6 [PMID] 1954824.

Grants

Sep 2023 – Sep 2024
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders
Role: Co-Project Director/Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022 – Sep 2023
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders
Role: Co-Project Director/Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Jun 2022 ACTIVE
Hemophilia Treatment Centers (SPRANS)
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Dec 2021 ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Sep 2021 – Sep 2022
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders
Role: Co-Project Director/Principal Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2021 ACTIVE
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study with a Long-Term, Open-label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients with Hemophilic Arthropathy
Role: Principal Investigator
Funding: IQVIA Holdings via TREMEAU PHARMACEUTICALS
Aug 2021 ACTIVE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via TAKEDA DEVELOPMENT CENTER AMERICAS INC
Jul 2021 – Jun 2022
University of Florida Hemphilia Treatment Center (HTC)
Role: Principal Investigator
Funding: HEMOPHILIA OF GEORGIA
Jun 2021 – May 2022
Southeast Region Comprehensive and Diagnostic Bleeding Treatment Center Program.
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
May 2021 ACTIVE
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via JANSSEN RESEARCH AND DEVELOPMENT
Nov 2020 – Dec 2022
Advisory Services Agreement for development of a modified cTTP publication entitled Treatment of Congenital Thrombotic Thrombocytopenia Purpura: A New Paradigm
Role: Principal Investigator
Funding: KEDRION BIOPHARMA
Oct 2020 – Oct 2022
A Multicenter, Post-Marketing Registry Study of COAGADEX in the Peri-operative Management of Patients with Moderate or Severe Hereditary Factor X Deficiency Undergoing Major surgery
Role: Principal Investigator
Funding: ATLANTIC RESEARCH GROUP via *BIO PRODUCTS LABORATORY
Sep 2020 – Sep 2021
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Jun 2020 – May 2021
Hemophilia Treatment Centers (SPRANS) Southeast Region Maternal and Child Health Bureau (MCHB) Bleeding Disorders Program
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Jan 2020 – Aug 2022
Prospective and retrospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice
Role: Principal Investigator
Funding: IQVIA Holdings via BAXALTA INNOVATIONS GMBH
Oct 2019 – Dec 2021
Quality of care for inferior vena cava filters at UF Health Shands Hospital
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Sep 2019 – Sep 2020
Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Aug 2019 – Nov 2019
Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno- associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco- Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B
Role: Principal Investigator
Funding: MEDPACE via UNIQURE BIOPHARMA BV
Jun 2019 – May 2020
Southeast Region Comprehensive and Diagnostic Bleeding Treatment Center Program.
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Oct 2018 – Aug 2022
A Prospective Non-Interventional Study of Bleeding Episodes, Factor VIII Infusions, and Patient-Reported Outcomes in Individuals with Severe Hemophilia A
Role: Principal Investigator
Funding: DRUGDEV INC via BIOMARIN PHARMACEUTICAL
Sep 2018 – Sep 2020
Public Health Surveillance for the Prevention of Complications of Bleeding Disorders Project.
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2018 – Oct 2023
ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via SANOFI US SERVICES
Jul 2018 – Aug 2022
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via SANOFI US SERVICES
Jun 2018 – May 2019
Southeast Region Comprehensive and Diagnostic Bleeding Treatment Center Program
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Sep 2017 – Sep 2018
Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2017 – Oct 2022
A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via DIMENSION THERAPEUTICS INC
Jul 2017 – Apr 2022
A prospective, phase 3, open-label, international multicenter study on efficacy and safety of prophylaxis with rVWF in severe von Willebrand Disease
Role: Principal Investigator
Funding: BAXALTA US
Jun 2017 – May 2018
Southeast Region Maternal and Child Health Bureau Bleeding Disorders Program
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN
Dec 2016 – Nov 2022
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Role: Principal Investigator
Funding: GENENTECH INC
Dec 2016 – Apr 2019
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Role: Principal Investigator
Funding: GENENTECH INC
Sep 2016 – Sep 2017
Community Counts Public Health Surveillance for Bleeding Disorders Project
Role: Co-Investigator
Funding: HEMOPHILIA OF GEORGIA via CTRS FOR DISEASE CONTROL AND PREVENTION
Jun 2016 – Mar 2022
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Role: Principal Investigator
Funding: IQVIA Holdings via JANSSEN PHARMACEUTICA INC
Jun 2016 – Mar 2019
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Role: Principal Investigator
Funding: IQVIA Holdings via JANSSEN RESEARCH AND DEVELOPMENT
Apr 2016 – Apr 2019
A PHASE I/II OPEN LABEL SAFETY AND DOSE FINDING STUDY OF ADENO ASSOCIATED VIRUS (AAV) RH 10 MEDIATED GENE TRANSFER…
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via DIMENSION THERAPEUTICS INC
Dec 2015 – Sep 2022
POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A
Role: Principal Investigator
Funding: IQVIA Holdings via BAXALTA US
Dec 2015 – Dec 2018
POST-MARKETING NON-INTERVENTIONAL SAFETY EVALUATION OF OBIZUR IN THE TX OF BLEEDING EPISODES FOR PATIENTS W/ ACQUIRED..
Role: Principal Investigator
Funding: IQVIA Holdings via BAXTER INTERNATIONAL
Jul 2013 – Jun 2016
Development and Implementation of an Intervention to Improve Inferior Vena Cava Filter Retrieval Rates: A Pilot Feasibility Study
Role: Principal Investigator
Funding: AMER SOC OF HEMATOLOGY
Jun 2013 – May 2017
Southeast Region Comprehensive and Diagnostic Bleeding Disorders Treatment Center Program
Role: Project Manager
Funding: HEMOPHILIA OF GEORGIA via US HLTH RESOURCES AND SERV ADMN

Education

Fellowship – Hematology and Oncology
2010 · University of Florida
Residency – Internal Medicine
2007 · University of Florida
Medical Degree
2004 · University of Florida

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Addresses:
Business Mailing:
1600 SW ARCHER RD
GAINESVILLE FL 32610
Business Street:
1600 SW ARCHER ROAD SHANDS HOSPITAL
BG-20 BASIC SCIENCE
HEALTH SCIENCE CENTER
GAINESVILLE FL 32610